Peter Riedell to Leukemia, Lymphocytic, Chronic, B-Cell
This is a "connection" page, showing publications Peter Riedell has written about Leukemia, Lymphocytic, Chronic, B-Cell.
Connection Strength
0.410
-
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 08 19; 402(10402):641-654.
Score: 0.213
-
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 03 24; 139(12):1794-1806.
Score: 0.196